1. Home
  2. PWP vs ANAB Comparison

PWP vs ANAB Comparison

Compare PWP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perella Weinberg Partners

PWP

Perella Weinberg Partners

HOLD

Current Price

$23.92

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$50.24

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PWP
ANAB
Founded
2006
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PWP
ANAB
Price
$23.92
$50.24
Analyst Decision
Hold
Buy
Analyst Count
3
11
Target Price
$24.50
$60.18
AVG Volume (30 Days)
1.2M
407.6K
Earning Date
02-06-2026
02-26-2026
Dividend Yield
1.15%
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$750,903,000.00
$169,467,000.00
Revenue This Year
$34.64
$135.51
Revenue Next Year
$15.43
N/A
P/E Ratio
$51.79
N/A
Revenue Growth
N/A
196.42
52 Week Low
$14.12
$12.21
52 Week High
$25.93
$52.47

Technical Indicators

Market Signals
Indicator
PWP
ANAB
Relative Strength Index (RSI) 67.66 57.13
Support Level $21.20 $48.15
Resistance Level $25.93 $51.74
Average True Range (ATR) 1.23 2.74
MACD 0.10 0.09
Stochastic Oscillator 63.49 77.88

Price Performance

Historical Comparison
PWP
ANAB

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: